Role of bone marrow stromal cells in the generation of human CD8+ regulatory T cells

Human Immunology

Volumn 69, Issue 11, 2008, Pages 755-759

  Poggi, Alessandro ^a   Zocchi, Maria Raffaella ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

CD8+ regulatory T cells; Lymphocyte proliferation; Mesenchymal stem cells; Stromal cells

Indexed keywords

CD3 ANTIGEN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 10; MESSENGER RNA; PROSTAGLANDIN E2; SCATTER FACTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BONE MARROW CELL; BONE MARROW STROMAL CELL; CD25 CD28 T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CELLULAR IMMUNITY; COCULTURE; CYTOKINE PRODUCTION; DOWN REGULATION; FIBROBLAST; GENE EXPRESSION; HUMAN; IMMUNOMODULATION; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STROMA CELL;

ANTIGENS, CD28; ANTIGENS, CD3; BONE MARROW CELLS; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL PROLIFERATION; CYCLOSPORINE; DINOPROSTONE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; RECEPTORS, ANTIGEN, T-CELL; RNA, MESSENGER; STROMAL CELLS; T-LYMPHOCYTE SUBSETS; TRANSFORMING GROWTH FACTOR BETA;

EID: 57649106633     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2008.08.278     Document Type: Article

References (64)

1. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance Cell 2000;101:455-8.
2. + adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 177 (2006) 246-254
3. + regulatory T cells from human peripheral blood. J Immunol 166 (2001) 7282-7289
4. Strom T.B., and Carpenter C.B. Prostaglandin as an effective anti-rejection therapy in rat renal allograft recipient. Transplantation 35 (1983) 279-281
5. + T cells. J Immunol 175 (2005) 1483-1490
6. + regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 200 (2004) 1123-1134
7. Xystrakis E., Dejean A.S., Bernard I., Druet P., Liblau R., Gonzales-Dunia D., et al. Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. Blood 104 (2004) 3294-3301
8. + regulatory T cells generated ex-vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus host disease with lupus-like syndrome. J Immunol 172 (2004) 1531-1539
9. + regulatory T cells in human ovarian carcinoma. Cancer Res 65 (2005) 5020-5026
10. Roncarolo M.G., Gregori S., Battaglia M., Bacchetta R., Fleischhauer K., and Levings M.K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212 (2006) 28-50
11. Groux H. Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation 15 (2003) 8S-18S
12. + regulatory thymocytes. J Exp Med 196 (2002) 379-387
13. Fontenot J.D., Rasmussen J.P., Gavin M.A., and Rudensky A.Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6 (2005) 1142-1151
14. + suppressor T cells: more questions than answers. Nat Rev Immunol 2 (2002) 389-400
15. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 (2004) 531-562
16. Von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 6 (2005) 338-343
17. Curtin J.F., Candolfi M., Fakhouri T.M., Liu C., Alden A., Edwards M., et al. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS ONE 3 (2008) e1983 1-17
18. Degl'Innocenti E., Grioni M., Capuano G., Jachetti E., Freschi M., Bertilaccio M.T., et al. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res 68 (2008) 292-300
19. Broere F., Wieten L., Klein Koerkamp E.I., van Roon J.A., Guichelaar T., Lafeber F.P., et al. Oral or nasal antigen induces regulatory T cells that suppress arthritis and proliferation of arthritogenic T cells in joint draining lymph nodes. J Immunol 181 (2008) 899-906
20. Witz I.P. Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res 100 (2008) 203-229
21. Lutsiak M.E., Tagaya Y., Adams A.J., Schlom J., and Sabzevari H. Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. J Immunol 180 (2008) 5871-5881
22. Amé-Thomas P., Maby-El Hajjami H., Monvoisin C., Jean R., Monnier D., Caulet-Maugendre S., et al. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood 109 (2007) 693-702
23. Alves P.M., Lévy N., Stevenson B.J., Bouzourene H., Theiler G., Bricard G., et al. Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer. Cancer Immun 8 (2008) 1-11
24. Scadden D.T. The stem-cell niche as an entity of action. Nature 441 (2006) 1075-1079
25. Iwamoto S., Mihara K., Downing J.R., Pui C.H., and Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 117 (2007) 1049-1057
26. Prevosto C., Zancolli M., Canevali P., Zocchi M.R., and Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92 (2007) 895-904
27. Papayannopoulou T., and Scadden D.T. Stem-cell ecology and stem cells in motion. Blood 111 (2008) 3923-3930
28. El-Badri N.S., Hakki A., Ferrari A., Shamekh R., and Good R.A. Autoimmune disease: is it a disorder of the microenvironment?. Immunol Res 41 (2008) 79-86
29. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
30. Sekiya I., Larson B.L., Smith J.R., Pochampally R., Cui J.G., and Prockop D.J. Expansion of human adult stem cells from bone marrow stroma: conditions that maximaze the yields of early progenitors and evaluate their quality. Stem Cells 20 (2002) 530-541
31. Kawada H., Fujita J., Kinjo K., Matsuzaki Y., Tsuma M., Miyatake H., et al. Non-hematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 104 (2004) 3581-3587
32. Lazarus H.M., Haynesworth S.E., Gerson S.L., Rosenthal N.S., and Caplan A.I. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 16 (1995) 557-564
33. Horwitz E.M., Gordon P.L., Koo W.K., Marx J.C., Neel M.D., McNall R.Y., et al. Isolated allogeneic bone-marrow derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 99 (2002) 8932-8937
34. Woodbury D., Schwarz E.J., Prockop D.J., and Black I.B. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 61 (2000) 364-370
35. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., and Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75 (2003) 389-397
36. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Stucchi C., and Cleris L. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99 (2002) 3838-3843
37. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 5 (2003) 485-489
38. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., and Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57 (2003) 11-20
39. Potian J.A., Aviv H., Ponzio N.M., Harrison J.S., and Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 171 (2003) 3426-3434
40. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102 (2003) 3837-3844
41. Beyth S., Borovsky Z., Mevorach D., Liebergall M., Gazit Z., Aslan H., et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T cell unresponsiveness. Blood 105 (2005) 2214-2219
42. Meisel R., Zibert A., Laryea M., Gobel U., Daubener U., and Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (2004) 4619-4621
43. Aggarwal S., and Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005) 1815-1822
44. Augello A., Tasso R., Negrini S.M., Amateis A., Indiveri F., Cancedda R., et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed cell death 1 pathway. Eur J Immunol 35 (2005) 1482-1490
45. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hussan M., Uzunel M., et al. Treatment of severe acute graft-versus host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
46. Poggi A., and Zocchi M.R. Antigen presenting cells and stromal cells trigger human natural killer lymphocytes to autoreactivity: evidence for the involvement of natural cytotoxicity receptors (NCR) and NKG2D. Clin Dev Immunol 13 (2006) 325-336
47. Jones S., Horwood N., Cope A., and Dazzi F. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol 179 (2007) 2824-2831
48. Filaci G., Bacilieri S., Fravega M., Monetti M., Contini P., Ghio M., et al. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol 166 (2001) 6452-6457
49. Filaci G., Fenoglio D., Fravega M., Ansaldo G., Borgonovo G., Traverso P., et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 179 (2007) 4323-4334
50. Koenen H.J., Smeets R.L., Vink P.M., Rijssen E.V., Boots A.M., and Joosten I. Human CD25highFoxp3pos regulatory T-cells differentiate into IL-17 producing cells. Blood 112 (2008) 2340-2352
51. Luo B.H., Carman C.V., and Springer T.A. Structural basis of integrin regulation and signaling. Annu Rev Immunol 25 (2007) 619-647
52. Takagi J., and Springer T.A. Integrin activation and structural rearrangement. Immunol Rev 186 (2002) 141-163
53. Zeiser R., Nguyen V.H., Beilhack A., Buess M., Schulz S., Baker J., et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108 (2006) 390-399
54. Tewari K., Nakayama Y., and Suresh M. Role of direct effects of IFN-gamma on T cells in the regulation of CD8 T cell homeostasis. J Immunol 179 (2007) 2115-2125
55. Naganuma M., Wiznerowicz E.B., Lappas C.M., Linden J., Worthington M.T., and Ernst P.B. Cutting edge: critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J Immunol 177 (2006) 2765-2769
56. Cortesini R., LeMaoult J., Ciubotariu R., and Cortesini N.S. CD8+CD28- T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev 182 (2001) 201-206
57. Filaci G., Fravega M., Fenoglio D., Rizzi M., Negrini S., Viggiani R., et al. Non-antigen specific CD8+ T suppressor lymphocytes. Clin Exp Med 4 (2004) 86-92
58. Filaci G., and Suciu-Foca N. CD8+ T suppressor cells are back to the game: are they players in autoimmunity?. Autoimmun Rev 1 (2002) 279-283
59. Smith T.R., and Kumar V. Revival of CD8(+) Treg-mediated suppression. Trends Immunol 7 (2008) 337-342
60. Poggi A., Prevosto C., Massaro A.M., Negrini S., Urbani S., Pierri I., et al. Interaction between human natural killer cells and bone marrow stromal cells induces NK cell triggering. Role of NKp30 and NKG2D receptors. J Immunol 175 (2005) 6352-6360
61. Poggi A., Massaro A.M., Negrini S., Pierri I., Balocco M., Michelis G., et al. Evidence for killing of mesenchymal stem cells (MSC) by autologous natural killer lymphocytes. Blood (ASH Annual Meeting Abstracts) 104 (2004) 1290
62. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., and Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107 (2006) 1484-1490
63. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis C.N., and Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24 (2006) 74-85
64. Wynn T.A. Common and inique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117 (2007) 524-529